ReviewFrontiers in pharmacology2025
Licorice in nephropathy treatment: phytochemical compositions and pharmacological mechanisms.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic potential of glycyrrhizic acid in inflammation-related diseases: from HMGB1-oriented molecular insights to preclinical application.Archives of pharmacal research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nephropathy refers to a wide range of kidney dysfunction and is a highly prevalent condition worldwide, often associated with several disorders, including inflammation, oxidative stress, apoptosis, epithelial-mesenchymal transition (EMT), autophagy, and the deposition of extracellular matrix (ECM). Licorice has been used in China for thousands of years to treat nephropathy, while the underlying mechanisms are still unclear. The triterpenoid and flavonoid compounds are the main components of licorice. The main bioactive components of licorice against nephropathy are glycyrrhizic acid, glycyrrhetinic acid, isoliquiritigenin, glabridin, isoliquiritin and licochalcone A. These components alleviate kidney injury through anti-inflammatory, anti-oxidative stress, anti-apoptosis, promoting autophagy, inhibiting EMT, and reducing ECM deposition by targeting the signaling pathways of NF-κB, TGF-β1, JNK, MAPK, p53, STAT3 and HMGB1. This review will provide a new insight to clarify the bioactive components of licorice against nephropathy and their corresponding mechanisms, which aims to provide useful information for the further application of licorice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.